Next Article in Journal
Perceptions of Health Care Providers Concerning Patient and Health Care Provider Strategies to Limit Out-of-Pocket Costs for Cancer Care
Previous Article in Journal
Microbes and Colorectal Cancer: Is There a Relationship?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 4
10.3747/co.v16i4.469
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer

by
S. Dent
1,*,
Sh. Verma
1,
J. Latreille
2,
D. Rayson
3,
M. Clemons
4,
J. Mackey
5,
Su. Verma
6,
J. Lemieux
7,
L. Provencher
8,
S. Chia
9,
B. Wang
10 and
K. Pritchard
6
1
The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON, Canada
2
Réseau Cancer Montérégie and Université de Sherbrooke, Longueuil, QC, Canada
3
Atlantic Clinical Cancer Research Unit and QEII Cancer Care Program, Halifax, NS, Canada
4
Princess Margaret Hospital, Toronto, ON, Canada
5
Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
6
Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, ON, Canada
7
Centre de Recherche du Centre Hospitalier affilié universitaire de Québec, Quebec City, QC, Canada
8
Hôpital du Saint-Sacrement, Quebec City, QC, Canada
9
British Columbia Cancer Agency–Vancouver Centre, Vancouver, BC, Canada
10
Remedy Communications Limited, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(4), 25-35; https://doi.org/10.3747/co.v16i4.469
Submission received: 4 May 2009 / Revised: 3 June 2009 / Accepted: 2 July 2009 / Published: 1 August 2009

Abstract

The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (her2), was the first her2-targeted therapy that clearly demonstrated a significant clinical benefit for women with her2-overexpressing metastatic breast cancer (mbc). However, in recent years it has become increasingly apparent that, when trastuzumab is used in the first-line setting in combination with chemotherapy, most women eventually develop progressive disease. Determining the treatment options available to women who have progressed while on trastuzumab therapy has been hampered by a paucity of high-quality published data. In addition, with the standard use of trastuzumab in the adjuvant setting (for eligible her2-positive patients), the role of anti-her2 agents for patients who experience a breast cancer relapse has become a clinically relevant question. This manuscript reviews current available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other her2-targeted agents in two key mbc indications: (1) Treatment for women with her2-positive mbc progressing on trastuzumab (that is, treatment beyond progression); (2) Treatment for women with her2-positive mbc recurring following adjuvant trastuzumab (that is, re-treatment). The suggestions set out here will continue to evolve as data and future trials with trastuzumab and other her2-targeted agents emerge.
Keywords: metastatic breast cancer; trastuzumab; treatment beyond progression; re-treatment; her2-targeted therapy metastatic breast cancer; trastuzumab; treatment beyond progression; re-treatment; her2-targeted therapy

Share and Cite

MDPI and ACS Style

Dent, S.; Verma, S.; Latreille, J.; Rayson, D.; Clemons, M.; Mackey, J.; Verma, S.; Lemieux, J.; Provencher, L.; Chia, S.; et al. The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer. Curr. Oncol. 2009, 16, 25-35. https://doi.org/10.3747/co.v16i4.469

AMA Style

Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, et al. The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer. Current Oncology. 2009; 16(4):25-35. https://doi.org/10.3747/co.v16i4.469

Chicago/Turabian Style

Dent, S., Sh. Verma, J. Latreille, D. Rayson, M. Clemons, J. Mackey, Su. Verma, J. Lemieux, L. Provencher, S. Chia, and et al. 2009. "The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer" Current Oncology 16, no. 4: 25-35. https://doi.org/10.3747/co.v16i4.469

APA Style

Dent, S., Verma, S., Latreille, J., Rayson, D., Clemons, M., Mackey, J., Verma, S., Lemieux, J., Provencher, L., Chia, S., Wang, B., & Pritchard, K. (2009). The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer. Current Oncology, 16(4), 25-35. https://doi.org/10.3747/co.v16i4.469

Article Metrics

Back to TopTop